Sort
15,273 grants matching “antimicrobial resistance”
UVPD-MS Characterization of Lipopolysaccharides
$297,043Jennifer S Brodbelt · University Of Texas At Austin · R01 · FY2019 · GM
UVPD-MS Characterization of Lipopolysaccharides
$297,043Jennifer S Brodbelt · University Of Texas At Austin · R01 · FY2018 · GM
UVPD-MS Characterization of Lipopolysaccharides
$297,043Jennifer S Brodbelt · University Of Texas At Austin · R01 · FY2017 · GM
Triple action chimera: eradication of nasal S. aureus by cell wall hydrolases
$297,000David Matthew Donovan · U.S. Agricultural Research Center · R01 · FY2010 · AI
Human Cathelicidin-Based Novel Antimicrobial Peptides
$297,000Guangshun Wang · University Of Nebraska Medical Center · R56 · FY2010 · AI
Mechanism of KDO 8-P and DAH 7-P Synthase
$296,966University Of Michigan At Ann Arbor · R01 · FY2002 · GM
Mechanism of KDO 8-P and DAH 7-P Synthase
$296,966University Of Michigan At Ann Arbor · R01 · FY2003 · GM
Mechanism of KDO 8-P and DAH 7-P Synthase
$296,966University Of Michigan At Ann Arbor · R01 · FY2004 · GM
A broad spectrum anti-gonorrhea immunotherapeutic
$296,920Keith Wycoff · Planet Biotechnology, Inc. · R41 · FY2025 · AI
Alpha-AApeptides as a novel class of antimicrobial biomaterials
$296,818Jianfeng Cai · University Of South Florida · R01 · FY2016 · GM
Development of a Rapid and Scalable Method for Bacteriophage Manufacture and Purification
$296,787Michael Billard · Adaptive Phage Therapeutics, Inc. · N43 · FY2021 · AI
Demonstration of Near Zero Antibiotic Prescribing for Acute Bronchitis
$296,741Jeffrey A. Linder · Brigham And Women'S Hospital · R18 · FY2012 · HS
Development of Broad-Spectrum Cyclic Amphiphilic Peptides against Multidrug-Resistant Bacteria
$296,643Assad Kazeminy · Ajk Biopharmaceutical Llc · R41 · FY2023 · AI
Inhibitors of c-di-GMP synthesis and degradation
$296,625Stephen Lory · Harvard Medical School · R01 · FY2010 · AI
Inhibitors of c-di-GMP synthesis and degradation
$296,625Stephen Lory · Harvard Medical School · R01 · FY2009 · AI
Partnership for Research in Emerging Viral Infections-Sierra Leone (PREVSL)
$296,608John Scribner Schieffelin · Tulane University Of Louisiana · D43 · FY2025 · TW
Applying Association Mining and Group Based Trajectory Analyses to Characterize Spatial Temporal Trends of Community-Onset Antibiotic Resistant Staphylococcus aureus Infections in Children
$296,577Lilly Hsi-Chih Immergluck · Morehouse School Of Medicine · U54 · FY2024 · MD
Antibiotic discovery from a new genus of uncultured bacteria.
$296,521Amy Lynn Spoering · Novobiotic Pharmaceuticals, Llc · R43 · FY2021 · AI
AMONG TOP DISEASE CHALLENGES FOR FARMED TROUT ARE PATHOGENIC FLAVOBACTERIA, PARTICULARLY FLAVOBACTERIUM PSYCHROPHILUM (FP). UNFORTUNATELY, FEW FDA-APPROVED TREATMENT OPTIONS EXIST, AND EFFECTIVE VACCINES ARE CURRENTLY UNAVAILABLE IN THE USA. OUR PREVIOUS USDA-FUNDED STUDIES DOCUMENTED SUBSTANTIAL FP DIVERSITY AND LINKED CERTAIN STRAINS TO DISEASE OUTBREAKS IN US TROUT FARMS, SOME OF WHICH ALSO RESISTED APPROVED ANTIMICROBIALS (OXYTETRACYCLINE, SULFONAMIDES AND FLORFENICOL), AND THAT MAY POSSESS HEIGHTENED TRANSMISSIBILITY OWING TO BIOFILM FORMATION OR ENVIRONMENTAL PERSISTENCE. WE ALSO IDENTIFIED MULTIPLE FP-VARIANTS THAT, DESPITE CAUSING DISEASE, WERE FP BY SEQUENCE ANALYSIS BUT COULD NOT BE CHARACTERIZED USING STANDARD ASSAYS, INCLUDING ROUTINE DIAGNOSTIC TESTS AND POOR GROWTH ON TYPICAL MEDIA. OUR OVERARCHING GOAL IS TO ACCOUNT FOR THIS DIVERSITY AND REDUCE FP-INDUCED TROUT LOSSES BY IMPROVING FLAVOBACTERIAL DIAGNOSTIC CAPACITY,MODIFYING MANAGEMENT PRACTICES TO ACCOUNT FOR STRAIN-BASED PERSISTENCE AND TRANSMISSION STRATEGIES, AND EXPLORING NOVEL VACCINATION TACTICS BY: 1) DEVELOPING RAPID/SENSITIVE MOLECULAR AND CULTURE-BASED DIAGNOSTICS TO DETECT ALL FP-VARIANTS; 2) ELUCIDATING HOW FP-STRAIN VARIATION IN BIOFILM-FORMING CAPACITY, ENVIRONMENTAL PERSISTENCE, AND TRANSMISSION CONTRIBUTE TO DISEASE ASSOCIATED LOSSES, AND MODIFY MANAGEMENT ACCORDINGLY; 3) EVALUATE NON-VIRULENT NON-FP FLAVOBACTERIA AS VACCINE CANDIDATES AGAINST FP. THIS RESEARCH WILL IMPROVE FARMED-TROUT PRODUCTION/PROFITABILITY IN SHORT-TERM VIA: A) IMPROVED DISEASE DIAGNOSIS/TIMELY INTERVENTION; B) REDUCED DISEASE LOSSES THROUGH TARGETED MANAGEMENT. PRODUCTION/PROFITABILITY WILL IMPROVE MEDIUM-TERM VIA POTENTIAL VACCINE DEVELOPMENT AND REDUCING ANTIBIOTIC USE. THIS PROPOSAL ADDRESSES CRITICAL DISEASE ISSUES IMPACTING COMMERCIAL AQUACULTURE SPECIES PRIORITY OF USDA NIFA SPECIAL RESEARCH GRANTS PROGRAM, GOALS 2&4 OF 2018-2022 USDA STRATEGIC GOALS, AND THE ANIMAL HEALTH AND PRODUCTION AFRI PRIORITY AREA (2008 FARM BILL).
$296,515Michigan State University · · FY2019 · National Institute of Food and Agriculture
Augmentation of Innate Anti-Microbial Immunity by TLR4 Agonists
$296,459Edward R Sherwood · Vanderbilt University Medical Center · R01 · FY2016 · GM
Biosynthesis of Enterobacterial Common Antigen
$296,400Henry M. Jackson Fdn For The Adv Mil/Med · R01 · FY2003 · GM
Biosynthesis of Enterobacterial Common Antigen
$296,400Henry M. Jackson Fdn For The Adv Mil/Med · R01 · FY2002 · GM
Biosynthesis of Enterobacterial Common Antigen
$296,400Henry M. Jackson Fdn For The Adv Mil/Med · R01 · FY2001 · GM
Biosynthesis of Enterobacterial Common Antigen
$296,400Henry M. Jackson Fdn For The Adv Mil/Med · R01 · FY2004 · GM
Protein and Chemical Modulation of Curli Amyloid Biogenesis
$296,372Matthew R Chapman · University Of Michigan At Ann Arbor · R01 · FY2016 · GM